Newsfeeds - Spark Newswire

3 minute read

Benzinga’s ‘Stock Whisper’ Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet

March 18, 4:36 PM

Investors are on the hunt for undervalued, underfollowed and emerging stocks when it comes to spotting opportunities. Retail traders have countless methods at their disposal to uncover new information.

AMD

3 minute read

S&P 500 Down Over 1%; ThermoGenesis Shares Spike Higher

By Lisa Levin

March 15, 3:11 PM

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 400 points on Wednesday. The Dow traded down 1.32% to 31,732.39 while the NASDAQ fell 0.24% to 11,400.70. The S&P 500, also fell, dropping, 1.11% to 3,875.80.

APEI

3 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

March 15, 1:30 PM

Gainers ThermoGenesis Holdings (NASDAQ:THMO) shares rose 78.7% to $3.77 during Wednesday’s regular session. As of 13:30 EST, this…

BLCM

3 minute read

Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

March 15, 1:20 PM

Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies.

$APE

1 minute read

Why Jounce Therapeutics Stock Is Moving Higher Today?

By Vandana Singh

March 15, 10:41 AM

The Board of Directors of Jounce Therapeutics Inc (NASDAQ:JNCE) confirmed that Concentra Biosciences LLC made an unsolicited and non-binding proposal to acquire 100%…

JNCE

1 minute read

M&A
News

Reported Late Tuesday March 14, Jounce Therapeutics Confirms Receipt Of Unsolicited Proposal From Concentra Biosciences To Acquire 100% Of The Co. For $1.80/Share Subject To Diligence And Availability Of At Least $130M Of Cash And Equivalents At Closin…

By Happy Mohamed

March 15, 1:15 AM

The Board of Directors (the "Board") of Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer

JNCE

1 minute read

SMBC Nikko Downgrades Jounce Therapeutics to Neutral

By Benzinga Newsdesk

February 24, 9:47 AM

SMBC Nikko analyst David Dai downgrades Jounce Therapeutics (NASDAQ:JNCE) from Outperform to Neutral.

JNCE

2 minute read

Redx and Jounce Merged To Form Redx; Redx Shareholders Will Own 63% and Jounce Shareholders 37% of Share Capital

By Benzinga Newsdesk

February 23, 4:23 AM

Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) today announce an unanimously recommended Business Combination of the two companies via a proposed all share merger transaction. Redx is a

JNCE

4 minute read

Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

December 28, 2:00 PM

Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.

$APE